Transition of Stable Pediatric Patients With Pulmonary Arterial Hypertension from Intravenous Epoprostenol to Intravenous Treprostinil

American Journal of Cardiology

Volumn 99, Issue 5, 2007, Pages 696-698

  Ivy, D Dunbar ^a   Claussen, Lori ^a   Doran, Aimee ^a  

^a CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN; CALCIUM CHANNEL STIMULATING AGENT; CLOPIDOGREL; DIGOXIN; DIURETIC AGENT; OXYGEN; PROSTACYCLIN; SILDENAFIL; UNIPROST; WARFARIN;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATALITY; FEMALE; FLUSHING; GASTROINTESTINAL SYMPTOM; HALF LIFE TIME; HEADACHE; HOSPITAL ADMISSION; HUMAN; INJECTION SITE INFECTION; JAW DISEASE; LEG PAIN; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RASH; RETROSPECTIVE STUDY; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ANTIHYPERTENSIVE AGENTS; CHILD; CHILD, PRESCHOOL; EPOPROSTENOL; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; INFUSIONS, INTRAVENOUS; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33847017687     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.119     Document Type: Article

References (11)

1. Barst R.J., McGoon M., Torbicki A., Sitbon O., Krowka M.J., Olschewski H., and Gaine S. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 40S-47S
2. Rashid A., and Ivy D. Pulmonary hypertension in children. Current Paediatr 16 (2006) 237-247
3. D'Alonzo G.E., Barst R.J., Ayres S.M., Bergofsky E.H., Brundage B.H., Detre K.M., Fishman A.P., Godring R.M., Groves B.M., Kernis J.T., et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115 (1991) 343-349
4. Barst R.J., Rubin L.J., McGoon M.D., Caldwell E.J., Long W.A., and Levy P.S. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 121 (1994) 409-415
5. Shapiro S.M., Oudiz R.J., Cao T., Romano M.A., Beckman X.L., Georgiou D., Mandayam S., Ginzton L.E., and Brundage B.H. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 30 (1997) 343-349
6. McLaughlin V.V., Genthner D.E., Panella M.M., and Rich S. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 338 (1998) 273-277
7. Badesch D.B., Abman S.H., Ahearn G.S., Barst R.J., McCrory D.C., Simonneau G., and McLaughlin V.V. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest 126 (2004) 35S-62S
8. Badesch D.B., McLaughlin V.V., Delcroix M., Vizza C.D., Olschewski H., Sitbon O., and Barst R.J. Prostanoid therapy for pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 56S-61S
9. McLaughlin V.V., Gaine S.P., Barst R.J., Oudiz R.J., Bourge R.C., Frost A., Robbins I.M., Tapson V.F., McGoon M.D., Badesch D.B., et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol 41 (2003) 293-299
10. Laliberte K., Arneson C., Jeffs R., Hunt T., and Wade M. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol 44 (2004) 209-214
11. Gomberg-Maitland M., Tapson V.F., Benza R.L., McLaughlin V.V., Krichman A., Widlitz A.C., and Barst R.J. Transition from intravenous epoprostenol to intravenous treprostinil in pulmonary hypertension. Am J Respir Crit Care Med 172 (2005) 1586-1589